News

Eli Lilly: The Bears Have Spoken Loud And Clear (Upgrade)
Eli Lilly and Company faces valuation pressure after disappointing Orforglipron results. Discover why now isn't the time to ...
Eli Lilly Shares Plummet 14% Toward Worst Day In 25 Years—Here’s Why It’s Down
Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...
UK Government, Eli Lilly Partner To Target Obesity Health Gaps
A UK government and Eli Lilly £85 million program will expand obesity care nationwide, offering digital, community, and ...
Novo Nordisk: Enough Is Enough
Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...
Danish drugmakers jump as Eli Lilly's weight-loss pill data disappoints
Shares in Novo Nordisk rose as much as 14% on Thursday after trial data from Eli Lilly's experimental weight-loss pill fell ...
Eli Lilly closer to breakthrough weight loss drug; shares tumble as some question results
Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...